| 0.88 0.04 (4.71%) | 03-10 11:17 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.12 | 1-year : | 1.23 |
| Resists | First : | 0.96 | Second : | 1.05 |
| Pivot price | 0.86  |
|||
| Supports | First : | 0.81 | Second : | 0.67 |
| MAs | MA(5) : | 0.86 |
MA(20) : | 0.9 |
| MA(100) : | 0.97 |
MA(250) : | 1.23 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 18.2 |
D(3) : | 19.9 |
| RSI | RSI(14): 45.5 |
|||
| 52-week | High : | 2.59 | Low : | 0.68 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NRSN ] has closed above bottom band by 40.9%. Bollinger Bands are 66.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.89 - 0.9 | 0.9 - 0.9 |
| Low: | 0.81 - 0.81 | 0.81 - 0.82 |
| Close: | 0.83 - 0.84 | 0.84 - 0.85 |
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Mon, 09 Mar 2026
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference - PR Newswire
Wed, 18 Feb 2026
ALS trial: NeuroSense drug extends survival by 14 months, cuts deaths 65% - Stock Titan
Wed, 21 Jan 2026
New Alzheimer’s treatment from NeuroSense gets U.S. patent through 2043 - Stock Titan
Wed, 21 Jan 2026
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease - PR Newswire
Thu, 04 Dec 2025
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 33 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 19.1 (%) |
| Held by Institutions | 1 (%) |
| Shares Short | 392 (K) |
| Shares Short P.Month | 574 (K) |
| EPS | -0.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.02 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -303.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -2.39 |
| PEG Ratio | 0 |
| Price to Book value | -43 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.43 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|